AR015940A1 - Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento - Google Patents

Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento

Info

Publication number
AR015940A1
AR015940A1 ARP980104798A ARP980104798A AR015940A1 AR 015940 A1 AR015940 A1 AR 015940A1 AR P980104798 A ARP980104798 A AR P980104798A AR P980104798 A ARP980104798 A AR P980104798A AR 015940 A1 AR015940 A1 AR 015940A1
Authority
AR
Argentina
Prior art keywords
manufacture
tetrazol
lives
medicinal product
derivatives containing
Prior art date
Application number
ARP980104798A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR015940(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR015940A1 publication Critical patent/AR015940A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Análogo de rapamicina que tiene la formula (I) o una sal o prodroga del mismo farmacéuticamente aceptable que es un agente inmunomodulador y esutil en el tratamiento de restenosis, enfermedades inmunes y autoinmunes, e inhibe cáncer, desarrolofungal , y el rechazo a los tejidos de post-transplante;y su uso para la manufactura de un medicamento.
ARP980104798A 1997-09-26 1998-09-25 Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento AR015940A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
AR015940A1 true AR015940A1 (es) 2001-05-30

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104798A AR015940A1 (es) 1997-09-26 1998-09-25 Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento

Country Status (28)

Country Link
EP (1) EP1015459B9 (es)
JP (1) JP3790424B2 (es)
KR (3) KR100833812B1 (es)
CN (1) CN1161360C (es)
AR (1) AR015940A1 (es)
AT (1) ATE297398T1 (es)
AU (1) AU745576B2 (es)
BG (1) BG64955B1 (es)
BR (1) BR9812305A (es)
CA (1) CA2303934C (es)
CO (1) CO5070656A1 (es)
CZ (1) CZ299365B6 (es)
DE (1) DE69830502T2 (es)
DK (1) DK1015459T3 (es)
ES (1) ES2244087T3 (es)
HK (1) HK1030771A1 (es)
HU (1) HU228368B1 (es)
IL (2) IL134607A0 (es)
NO (1) NO325813B1 (es)
NZ (2) NZ502896A (es)
PL (1) PL191212B1 (es)
PT (1) PT1015459E (es)
SI (1) SI1015459T1 (es)
SK (1) SK285408B6 (es)
TR (1) TR200000778T2 (es)
TW (1) TW557297B (es)
WO (1) WO1999015530A1 (es)
ZA (1) ZA988750B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE347908T1 (de) * 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
DE60324416D1 (de) 2002-05-16 2008-12-11 Novartis Ag Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
NZ536558A (en) 2002-05-27 2006-07-28 Novartis Ag Bis-aromatic alkanols
PL375698A1 (en) * 2002-09-06 2005-12-12 Abbott Laboratories Medical device having hydration inhibitor
RU2478378C2 (ru) 2002-09-24 2013-04-10 Новартис Аг Органические соединения
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7417065B2 (en) 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CN101048152A (zh) 2004-10-28 2007-10-03 惠氏公司 mTOR抑制剂在治疗子宫平滑肌瘤中的应用
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
ES2611307T3 (es) 2005-08-30 2017-05-08 University Of Miami Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
BRPI0714945B8 (pt) 2006-07-25 2021-05-25 Abbott Lab composições de análogo de rapamicina e processos para preparação de formas cristalinas de análogos de rapamicinas
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
CN102083397B (zh) 2008-04-17 2013-12-25 米歇尔技术公司 具有生物可吸收层的支架
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US20120115840A1 (en) 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
EP2379499B1 (en) 2008-12-18 2014-04-09 Novartis AG Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2462165B1 (en) 2009-08-03 2016-05-11 University of Miami Method for in vivo expansion of t regulatory cells
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2563391B1 (en) 2010-04-27 2020-08-26 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
SG11201401384UA (en) 2011-10-14 2014-09-26 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
SG11201502605PA (en) 2012-10-12 2015-05-28 Bristol Myers Squibb Co Crystalline forms of a factor xia inhibitor
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
SG11201404432QA (en) * 2012-11-30 2014-10-30 Hangzhou Zylox Pharma Co Ltd Rafamycin analogs and methods for making same
CA2897826C (en) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
IL307212A (en) 2014-01-31 2023-11-01 Bristol Myers Squibb Co Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors
NO2760821T3 (es) 2014-01-31 2018-03-10
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US10300070B2 (en) 2014-03-27 2019-05-28 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CA2940671A1 (en) 2014-04-07 2015-10-15 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
SG11201702895SA (en) 2014-10-08 2017-05-30 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
KR20180080230A (ko) 2015-11-11 2018-07-11 노파르티스 아게 미오스타틴 길항제의 용도, 이들을 함유하는 조합물 및 그의 용도
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
KR20190089005A (ko) 2016-11-23 2019-07-29 노파르티스 아게 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
WO2020023418A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3952947A4 (en) 2019-04-11 2024-07-03 Enclear Therapies Inc METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR
EP4240356A1 (en) 2020-11-03 2023-09-13 RDiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
CN116082362B (zh) * 2023-01-04 2024-05-10 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
CN1235608A (zh) * 1996-09-09 1999-11-17 美国家用产品公司 烷基化的雷帕霉素衍生物
AU4246197A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries

Also Published As

Publication number Publication date
EP1015459B1 (en) 2005-06-08
NO20001438L (no) 2000-05-26
PT1015459E (pt) 2005-09-30
KR100700319B1 (ko) 2007-03-29
NZ514778A (en) 2005-01-28
PL339455A1 (en) 2000-12-18
BG64955B1 (bg) 2006-10-31
TR200000778T2 (tr) 2000-07-21
SI1015459T1 (en) 2005-10-31
ZA988750B (en) 1999-04-01
NO325813B1 (no) 2008-07-21
NZ502896A (en) 2001-12-21
EP1015459A1 (en) 2000-07-05
BG104316A (en) 2000-12-29
HU228368B1 (en) 2013-03-28
DE69830502D1 (de) 2005-07-14
EP1015459B9 (en) 2005-10-12
CZ299365B6 (cs) 2008-07-02
ATE297398T1 (de) 2005-06-15
CA2303934C (en) 2010-01-26
DE69830502T2 (de) 2006-05-11
JP3790424B2 (ja) 2006-06-28
KR20060071092A (ko) 2006-06-26
PL191212B1 (pl) 2006-03-31
WO1999015530A1 (en) 1999-04-01
IL134607A0 (en) 2001-04-30
CA2303934A1 (en) 1999-04-01
BR9812305A (pt) 2000-09-05
HUP0004556A3 (en) 2001-12-28
KR100833812B1 (ko) 2008-05-30
CN1271361A (zh) 2000-10-25
SK4172000A3 (en) 2000-08-14
AU745576B2 (en) 2002-03-21
KR20010024298A (ko) 2001-03-26
KR100803639B1 (ko) 2008-02-19
DK1015459T3 (da) 2005-10-10
IL134607A (en) 2006-04-10
JP2001517671A (ja) 2001-10-09
HUP0004556A2 (hu) 2001-10-28
AU9581998A (en) 1999-04-12
TW557297B (en) 2003-10-11
CZ20001014A3 (cs) 2000-07-12
HK1030771A1 (en) 2001-05-18
CO5070656A1 (es) 2001-08-28
CN1161360C (zh) 2004-08-11
SK285408B6 (sk) 2007-01-04
KR20070086925A (ko) 2007-08-27
NO20001438D0 (no) 2000-03-20
ES2244087T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
AR015940A1 (es) Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
AR015900A1 (es) Una formulacion farmaceutica que comprende voriconazol o un derivado farmaceuticamente aceptable del mismo y un derivado de ciclodextrina.
BR0015605A (pt) Composição e uso
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ES2175127T3 (es) Derivados de la quinazolina y su uso.
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
AR034343A1 (es) Combinaciones farmaceuticas
ES2062100T3 (es) Empleo de acetil l-carnitina en el tratamiento terapeutico de cataratas y composiciones farmaceuticas utiles en este tratamiento.
BRPI0107493B8 (pt) substâncias para uso no tratamento de psoríase
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
DK0479093T3 (da) Oligosaccharidderivater og deres anvendelse som lægemidler
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
FI935066A (fi) 2-amino-1,2,3,4-tetrahydronaftalenderivat aktivt inverkande pao kardiovaskularsystemet, foerfaranden foer framstaellning av dem och farmaceutiska kompositioner innehaollande dem
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
DE59108697D1 (de) Protein C-haltige pharmazeutische Präparation als Mittel gegen Entzündungen
MX9302578A (es) Agentes antivirales.

Legal Events

Date Code Title Description
FG Grant, registration